We are generating a pipeline of potential patient treatment opportunities to address chronic neurologic disorders, including levodopa-induced dyskinesia in Parkinson’s disease (PD), multiple sclerosis, epilepsy and other indications.
Our proprietary lead product candidate is ADS-5102 is a chrono-synchronous amantadine therapy with potential applications across a number of chronic neurologic disorders. We are focusing initial development on the treatment of levodopa-induced dyskinesia (LID) in patients with PD and submitted a New Drug Application (NDA) for this indication to the U.S. Food and Drug Administration in October 2016.
We are also investigating ADS-5102 for the treatment of walking impairment in multiple sclerosis (MS) patients and considering developing it for other indications in PD, post-stroke walking impairment, and side effects induced by anti-psychotic drugs, such as tardive dyskinesia, akathesia and weight gain.
Leveraging our discovery platform, we have identified ADS-4101, a development candidate of an approved epileptic drug. We anticipate initiating a Phase 1 clinical study of ADS-4101 for treatment of partial onset seizures in patients with epilepsy in 2016.
In our ADS-8800 series, we are developing for approval multiple fixed-dose combinations of ADS-5102, ADS-4101 and other single agents to expand the patient treatment reach associated with approved single agent medicines.